Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.56 |
| ▸ | NOS2 | P35228 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | GLA | P06280 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.51 |
| ▸ | NPY2R | P49146 | 1/20 | 0.51 |
| ▸ | NPY4R | P50391 | 1/20 | 0.51 |
| ▸ | GNPAT | O15228 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS1 | P29475 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NRP1 | O14786 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736416 | 0.97 | CYP2C19 (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1736042 | 0.97 | CYP2C19 (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29613341 | 0.97 | CYP2C19 (0.59) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1736266 | 0.96 | NPY1R (0.55) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29355798 | 0.93 | NPY1R (0.51) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL29919341 | 0.91 | GNPAT (0.51) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1738257 | 0.90 | NPY1R (0.53) | CYP2C19NOS2CYP1A2GLATSHR | |
| Thymotrinan SCHEMBL15532089 | 0.90 | NPY1R (0.53) | CYP2C19NOS2CYP1A2GLATSHR | |
| Thymotrinan SCHEMBL1738371 | 0.90 | NPY1R (0.53) | CYP2C19NOS2CYP1A2GLATSHR | |
| SCHEMBL1738251 | 0.90 | CYP2C19 (0.51) | CYP2C19NOS2CYP1A2GLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110139368-B | Signal transmitting method and device | 中兴通讯股份有限公司 | 2025-02-18 | — | — | CN | claimed |
| CN-114716547-B | Binding proteins comprising antigen binding domains and methods of production and use thereof | 珠海丽禾医疗诊断产品有限公司 | 2023-11-21 | — | — | CN | claimed |
| CN-114716547-A | Binding protein comprising antigen binding domain and production method and application thereof | 珠海丽禾医疗诊断产品有限公司 | 2022-07-08 | — | — | CN | claimed |
| US-12511434-B2 | Data processing device and method for processing secret data | INFINEON TECHNOLOGIES AG (DE) | 2025-12-30 | — | — | US | disclosed |
| US-20250388901-A1 | ADVANCED RNA TARGETING (ARNATAR) | ARNATAR THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| EP-4653532-A2 | ADVANCED RNA TARGETING (ARNATAR) | Arnatar Therapeutics, Inc (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250206841-A1 | ANTI-TROPHOBLAST CELL SURFACE ANTIGEN 2 (TROP-2) ANTIBODIES | ADEPT BIOPHARMACEUTICAL AND TECHNOLOGY, LTD. (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4562158-A1 | ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGEN | Arnatar Therapeutics, Inc (US) | 2025-06-04 | — | — | EP | disclosed |
| US-20250101423-A1 | ADVANCED RNA TARGETING (ARNATAR) | ARNATAR THERAPEUTICS INC (US) | 2025-03-27 | — | — | US | disclosed |
| CN-110139368-B | Signal transmitting method and device | 中兴通讯股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2024259134-A1 | ADVANCED RNA TARGETING (ARNATAR) FOR ANGIOTENSINOGEN | ARNATAR THERAPEUTICS, INC (US) | 2024-12-19 | — | — | WO | disclosed |
| WO-2024137543-A1 | ADVANCED RNA TARGETING (ARNATAR) | ARNATAR THERAPEUTICS, INC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240193300-A1 | DATA PROCESSING DEVICE AND METHOD FOR PROCESSING SECRET DATA | INFINEON TECHNOLOGIES AG (DE) | 2024-06-13 | — | — | US | disclosed |
| CN-114716547-B | Binding proteins comprising antigen binding domains and methods of production and use thereof | 珠海丽禾医疗诊断产品有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-114716547-B | Binding proteins comprising antigen binding domains and methods of production and use thereof | 珠海丽禾医疗诊断产品有限公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-113923590-B | TOA positioning method under condition of uncertainty of anchor node position | 西北工业大学 | 2023-07-21 | — | — | CN | disclosed |
| CN-218675066-U | Iron core inductance test fixture | 殷华特殊金属有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-20220237304-A1 | Data Processing Device and Method for Processing Secret Data | INFINEON TECHNOLOGIES AG (DE) | 2022-07-28 | — | — | US | disclosed |
| CN-114716547-A | Binding protein comprising antigen binding domain and production method and application thereof | 珠海丽禾医疗诊断产品有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114716547-A | Binding protein comprising antigen binding domain and production method and application thereof | 珠海丽禾医疗诊断产品有限公司 | 2022-07-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388901-A1 | ADVANCED RNA TARGETING (ARNATAR) | NSUN2, RNMT, NSUN3 | CYP2C19 4850/4885NOS2 3865/4885CYP1A2 4615/4885 |
| US-12511434-B2 | Data processing device and method for processing secret data | ORAI1, CCKBR, SET | CYP2C19 3182/4885NOS2 1352/4885CYP1A2 4414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.